Chief Executive Officer, President & Director, Exelixis
Search every verified Michael Morrissey interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Michael Morrissey, as president and CEO of Exelixis, discussed the company's first quarter 2025 financial results in May 2025, reporting net product revenue of $513.3 million, a 36% year-over-year increase. He stated that the company was "excited about the trajectory of our business" and noted that Exelixis was increasing its full-year 2025 net product revenue guidance to between $2.05 billion and $2.15 billion. Morrissey also highlighted the approval of CABOMETYX for neuroendocrine tumors and said the company was advancing its pipeline, including the ZANZA trials. In December 2025, Morrissey, in his role as Norfolk District Attorney, spoke publicly for the first time since the conclusion of the Karen Read trial. He said that he was "much happier with the outcome today" regarding the Brian Walshe murder trial and expressed satisfaction with the work of law enforcement and his office. Morrissey explained his previous silence by stating that speaking out could "interfere with an individual's right to a fair trial." He added that he took the job "to speak for victims" and would continue to focus on that through his tenure.
“Given the strong momentum of Cabomedics in the first quarter, we're increasing our 2025 full-year financial guidance for net product revenues and total revenues by $100 million.”
“We're excited about the trajectory of our business and have the balance sheet and expected cash flow to advance our pipeline priorities, access new high conviction assets, and continue to repurchase shares when we believe they are undervalued.”
“For the board it was a no-brainer: Ukraine is the priority of our lifetimes in oncology.”
“Cancer doesn't wait for anything. We have the knowledge, the contacts, and the connections as a family to help people who are on the move from Ukraine, and we want to respond in as coordinated a fashion as we can to the crisis.”
Norfolk District Attorney Michael Morrissey, who hadn’t spoken publicly since the conclusion of the Karen Read trial last summer, answered questions about the controversial case after Monday’s conclusion of the Brian Walshe murder trial.
*Exelixis, Inc. (EXEL) Q1 2025 Earnings – Full Coverage* *Key Highlights:* *Financials* – Q1 net product revenue $513,300K, up 36% YoY; total revenue $555,000K; net income $159,600K; $400B global oncology market. *Operations* – CABOMETYX approved for NET; ZANZA trials on track; share repurchases $289,000K; tariffs impact ~1% via Canada manufacturing. *Strategy* – CEO Mike Morrissey emphasized pipeline growth; CFO Chris Senner raised guidance; CMO Amy Peterson focused ZANZA data; tariffs mitigated via EU IP. *Outlook* – Raised FY25 net product revenue guidance to $2,050,000K-$2,150,000…
Michael Morrissey speaks to ecancer at the 2022 World Cancer Congress in Geneva about how to maintain cancer care in times ...
On March 7, Mike Morrissey, the executive director of the European Cancer Organisation, approached the professional society's ...
https://ebdgroup.knect365.com/biotech-showcase/ Exelixis CEO Michael Morrissey speaks to Scrip senior writer Emily Hayes ...
Motley Fool Explorer advisor Simon Erickson interviews Exelixis President and CEO Mike Morrissey. Morrissey discusses how ...
Sign in to search the full transcript archive, filter by topic, and access every quote from Michael Morrissey.